These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 24638114

  • 1. Financial return-on-investment of ophthalmic interventions: a new paradigm.
    Brown MM, Brown GC, Lieske HB, Lieske PA.
    Curr Opin Ophthalmol; 2014 May; 25(3):171-6. PubMed ID: 24638114
    [Abstract] [Full Text] [Related]

  • 2. The Cost-Effectiveness of Ranibizumab for the Treatment of Diabetic Macular Edema.
    Brown GC, Brown MM, Turpcu A, Rajput Y.
    Ophthalmology; 2015 Jul; 122(7):1416-25. PubMed ID: 25935787
    [Abstract] [Full Text] [Related]

  • 3. Cataract surgery cost utility revisited in 2012: a new economic paradigm.
    Brown GC, Brown MM, Menezes A, Busbee BG, Lieske HB, Lieske PA.
    Ophthalmology; 2013 Dec; 120(12):2367-2376. PubMed ID: 24246824
    [Abstract] [Full Text] [Related]

  • 4. The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited.
    Brown GC, Brown MM, Lieske HB, Turpcu A, Rajput Y.
    Int J Retina Vitreous; 2017 Dec; 3():5. PubMed ID: 28289548
    [Abstract] [Full Text] [Related]

  • 5. SOCIETAL COSTS ASSOCIATED WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE UNITED STATES.
    Brown MM, Brown GC, Lieske HB, Tran I, Turpcu A, Colman S.
    Retina; 2016 Feb; 36(2):285-98. PubMed ID: 26428606
    [Abstract] [Full Text] [Related]

  • 6. Opportunities to Reduce Potential Bias in Ophthalmic Cost-Utility Analysis.
    Brown GC, Brown MM, Chaudhry I, Stein JD.
    JAMA Ophthalmol; 2021 Apr 01; 139(4):389-397. PubMed ID: 33538789
    [Abstract] [Full Text] [Related]

  • 7. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM, Brown GC, Brown HC, Peet J.
    Ophthalmology; 2008 Jun 01; 115(6):1039-1045.e5. PubMed ID: 17976724
    [Abstract] [Full Text] [Related]

  • 8. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.
    Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S.
    Ophthalmology; 2007 Jun 01; 114(6):1170-8. PubMed ID: 17320964
    [Abstract] [Full Text] [Related]

  • 9. A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration.
    Brown GC, Brown MM, Lieske HB, Lieske PA, Brown KS.
    Int J Retina Vitreous; 2015 Jun 01; 1():19. PubMed ID: 27847612
    [Abstract] [Full Text] [Related]

  • 10. Preference-based comparative effectiveness and cost–effectiveness: a review and relevance of value-based medicine for vitreoretinal interventions.
    Brown MM, Brown GC, Lieske HB, Lieske PA.
    Curr Opin Ophthalmol; 2012 May 01; 23(3):163-74. PubMed ID: 22487884
    [Abstract] [Full Text] [Related]

  • 11. Comparative effectiveness and cost-effectiveness of the implantable miniature telescope.
    Brown GC, Brown MM, Lieske HB, Lieske PA, Brown KS, Lane SS.
    Ophthalmology; 2011 Sep 01; 118(9):1834-43. PubMed ID: 21723614
    [Abstract] [Full Text] [Related]

  • 12. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
    Patel JJ, Mendes MA, Bounthavong M, Christopher ML, Boggie D, Morreale AP.
    J Eval Clin Pract; 2012 Apr 01; 18(2):247-55. PubMed ID: 20846318
    [Abstract] [Full Text] [Related]

  • 13. A cost-effectiveness analysis of three treatments for age-related macular degeneration.
    Gower EW, Cassard SD, Bass EB, Schein OD, Bressler NM.
    Retina; 2010 Feb 01; 30(2):212-21. PubMed ID: 19940805
    [Abstract] [Full Text] [Related]

  • 14. The burden of age-related macular degeneration: a value-based medicine analysis.
    Brown GC, Brown MM, Sharma S, Stein JD, Roth Z, Campanella J, Beauchamp GR.
    Trans Am Ophthalmol Soc; 2005 Feb 01; 103():173-84; discussion 184-6. PubMed ID: 17057801
    [Abstract] [Full Text] [Related]

  • 15. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB, Wittenborn JS, Lee PP, Wirth KE, Sorensen SW, Hoerger TJ, Saaddine JB.
    Ophthalmology; 2009 May 01; 116(5):823-32. PubMed ID: 19285730
    [Abstract] [Full Text] [Related]

  • 16. The comparative effectiveness and cost-effectiveness of vitreoretinal interventions.
    Brown MM, Brown GC, Brown HC, Irwin B, Brown KS.
    Curr Opin Ophthalmol; 2008 May 01; 19(3):202-7. PubMed ID: 18408494
    [Abstract] [Full Text] [Related]

  • 17. Value-based medicine and interventions for macular degeneration.
    Brown MM, Brown GC, Brown H.
    Curr Opin Ophthalmol; 2007 May 01; 18(3):194-200. PubMed ID: 17435425
    [Abstract] [Full Text] [Related]

  • 18. Cost-utility analysis of cataract surgery in the United States for the year 2018.
    Brown GC, Brown MM, Busbee BG.
    J Cataract Refract Surg; 2019 Jul 01; 45(7):927-938. PubMed ID: 31262482
    [Abstract] [Full Text] [Related]

  • 19. [Economic evaluation of bevacizumab versus ranibizumab in neovascular age-related macular degeneration].
    Li H, Li X, Xie F.
    Zhonghua Yan Ke Za Zhi; 2014 Jun 01; 50(6):426-33. PubMed ID: 25241975
    [Abstract] [Full Text] [Related]

  • 20. Value-Based Medicine and Pharmacoeconomics.
    Brown GC, Brown MM.
    Dev Ophthalmol; 2016 Jun 01; 55():381-90. PubMed ID: 26501688
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.